Novavax (NVAX) Q2 2024 earnings summary

Executive summary

• Entered a transformative partnership with Sanofi, receiving a $500M upfront payment and equity investment totaling up to $570M, with multi-billion dollar potential through milestones and royalties; Sanofi to assume primary commercial responsibility for COVID-19 vaccines in major markets starting 2025.

• Achieved Q2 2024 revenue of $415M and net income of $162M, ending the quarter with $1.1B in cash and equivalents.

• Shifted strategic focus to R&D and pipeline expansion, with cost reductions and a leaner operating model.

• Initiated regulatory filings for updated COVID-19 vaccine with FDA and EMA; manufacturing and distribution preparations underway for 2024–2025 season.

• Announced plans for Phase 3 trials of COVID-19-influenza combination and stand-alone influenza vaccines in Q4 2024.

Financial highlights

• Q2 2024 revenue was $415M, including $391M–$395.6M recognized from the Sanofi upfront payment and $19.9M–$20M in product sales.

• Net income for Q2 2024 was $162M–$162.4M, compared to a net loss in the prior year.

• R&D and SG&A expenses reduced by 34% year-over-year; further reductions planned.

• Cash and equivalents stood at $1.1B as of June 30, 2024, up from $584M at year-end 2023.

• Cost of sales for Q2 2024 was $46M–$46.2M, down from $56M in Q2 2023, with inventory write-downs and unutilized capacity costs.

Outlook and guidance

• Full-year 2024 revenue guidance: $700M–$800M, including $400M from Sanofi upfront payment and ~$425M in licensing/royalties.

• Product sales guidance for 2024: $275M–$375M, with most sales expected in Q4.

• Combined R&D and SG&A expense guidance for 2024: $700M–$750M; targeting below $500M in 2025 and below $350M in 2026.

• Sufficient capital to fund operations for at least one year from issuance date.

• Plans to deliver updated COVID-19 vaccine for 2024–2025 season, pending regulatory approvals.